-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Initiates Coverage On Viridian Therapeutics with Buy Rating, Announces Price Target of $47

Benzinga·11/19/2026 16:44:31
Listen to the news
B of A Securities analyst Daniel Giraldo initiates coverage on Viridian Therapeutics (NASDAQ:VRDN) with a Buy rating and announces Price Target of $47.